Gaithersburg-based MedImmune, the biologics research and development arm of AstraZeneca, has entered into a three-year partnership with the Clinical and Translational Science Institute at the University of California, San Francisco. The collaboration centers around CTSI’s Catalyst Awards program, which helps the university’s scientists translate their research into product development.
MedImmune will help the university move forward with promising research projects, focusing on the development of therapies for various diseases. The Catalyst Awards program will specifically call for research proposals that target one of MedImmune’s areas of interest, such as autoimmunity, neuroscience, infectious diseases and oncology.
During the three-year partnership, which can be extended, the university will supply the underlying research and MedImmune will contribute its commercialization know-how. The financial terms of the deal were not disclosed.
“UCSF’s innovative translational research capabilities combined with MedImmune’s industry experience in this area will help identify and nurture promising early science that can benefit MedImmune, UCSF researchers and ultimately patients,” Dr. Bing Yao, the company’s senior vice president and head of its Respiratory, Inflammation and Autoimmunity Innovative Medicines Unit, said in a statement. “We look forward to partnering with leading scientists at UCSF and growing our collective expertise within the Bay Area, one of the top global bioscience hubs.”